Ezetimibe Plus Atorvastatin Versus Atorvastatin Alone in Subjects With Primary Hypercholesterolemia (Study P03406)

Inclusion Criteria: * \>=18 years and \<= 75 years of age with LDL-C concentration \>= 2.6 mmol/L (100 mg/dL) to \<= 4.1 mmol/L (160 mg/dL) using the Friedewald calculation available at the time of randomization Visit 3 (Baseline Visit) and triglyceride concentrations of \< 3.99 mmol/L (350 mg/dL) at Baseline Visit * documented coronary heart disease * currently taking atorvastatin 10 mg daily and history has taken 80 % of daily doses for the preceding 6 weeks prior to Visit 3 * liver transaminases (ALT, AST) \< 50 % above the upper limit of normal, with no active liver disease, and CK \< 50 % above the upper limit of normal at Baseline Visit. * cholesterol lowering diet and exercise program for at least 4 weeks prior to and during the study, and stable weight history. * women receiving hormonal therapy, including hormone replacement, any estrogen antagonist/agonist, or oral contraceptives, must have been maintained on a stable dose and regimen for at least 8 weeks and continue same regimen during the study. * women of non-childbearing potential or using acceptable method of birth control. * subjects must be free of any clinically significant diseases other than hyperlipidemia or coronary heart disease that would interfere with study evaluations. Exclusion Criteria: * Subjects whose body mass index is \>=30 kg/sqm at baseline. * Subjects who consume \>14 alcoholic drinks per week. * Any condition or situation that, in the opinion of the investigator, might pose a risk to the subject or interfere with participation in the study. * Women who are pregnant or nursing. * Subjects who have not observed designated washout periods for prohibited medications (eg, potent inhibitors of CYP3A4, prescription or over-the-counter agents know to lower lipid levels, corticosteroids), or have been on a stable regimen of any cardiovascular agent for \<6 weeks.